These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11183179)

  • 1. Who shall not receive palivizumab?
    Brunvand L; Lindemann R; Grøgaard J
    Pediatrics; 2000 Oct; 106(4):866. PubMed ID: 11183179
    [No Abstract]   [Full Text] [Related]  

  • 2. Prophylaxis against respiratory syncytial virus in premature infants. IMpact-RSV Study Group.
    Top FH; Connor EM; Carlin DA
    Lancet; 2000 Mar; 355(9208):1014. PubMed ID: 10768456
    [No Abstract]   [Full Text] [Related]  

  • 3. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.
    Vogel AM; Lennon DR; Broadbent R; Byrnes CA; Grimwood K; Mildenhall L; Richardson V; Rowley S
    J Paediatr Child Health; 2002 Dec; 38(6):550-4. PubMed ID: 12410864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric case management for respiratory syncytial virus outcomes.
    Rieve JA
    Case Manager; 2002; 13(2):32-4. PubMed ID: 11901367
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunoprophylaxis for respiratory syncytial virus.
    Sánchez PJ
    Pediatr Infect Dis J; 2002 May; 21(5):473-8. PubMed ID: 12150195
    [No Abstract]   [Full Text] [Related]  

  • 6. [Palivizumab prophylaxis against respiratory syncytial virus. Should its indications be reviewed?].
    Salas Hernández S
    An Pediatr (Barc); 2004 Jan; 60(1):87-8. PubMed ID: 14718137
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention of respiratory syncytial virus infection with palivizumab.
    Thomas M; Bedford-Russell A; Sharland M
    Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates.
    Gortner L
    Klin Padiatr; 2017 Sep; 229(5):259-260. PubMed ID: 28926860
    [No Abstract]   [Full Text] [Related]  

  • 9. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease.
    Feltes TF; Sondheimer HM
    Expert Opin Biol Ther; 2007 Sep; 7(9):1471-80. PubMed ID: 17727335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palivizumab: an overview.
    Russell AB
    Hosp Med; 1999 Dec; 60(12):873-7. PubMed ID: 10707171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks.
    Resch B; Gusenleitner W; Müller WD; Haas J
    Eur J Clin Microbiol Infect Dis; 2006 Feb; 25(2):120-2. PubMed ID: 16491302
    [No Abstract]   [Full Text] [Related]  

  • 12. [Prophylaxis of respiratory syncytial virus infections with palivizumab].
    Danés Carreras I; Arnau De Bolós JM
    An Esp Pediatr; 2002 Apr; 56(4):289-91. PubMed ID: 11927094
    [No Abstract]   [Full Text] [Related]  

  • 13. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants: a note of caution.
    Suresh S; Schilling S; Dakin C; Harris MA
    J Paediatr Child Health; 2003 Nov; 39(8):637. PubMed ID: 14629536
    [No Abstract]   [Full Text] [Related]  

  • 14. Palivizumab for preterm infants. Is it worth it?
    Embleton ND; Harkensee C; Mckean MC
    Arch Dis Child Fetal Neonatal Ed; 2005 Jul; 90(4):F286-9. PubMed ID: 16036888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion.
    Meissner HC; Welliver RC; Chartrand SA; Law BJ; Weisman LE; Dorkin HL; Rodriguez WJ
    Pediatr Infect Dis J; 1999 Mar; 18(3):223-31. PubMed ID: 10093942
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevention of respiratory syncytial virus infection in infants.
    Handforth J; Sharland M; Friedland JS
    BMJ; 2004 May; 328(7447):1026-7. PubMed ID: 15117767
    [No Abstract]   [Full Text] [Related]  

  • 18. Comments on palivizumab (Synagis).
    Moler FW; Brown RW; Faix RG; Gilsdorf JR
    Pediatrics; 1999 Feb; 103(2):495-7. PubMed ID: 9925848
    [No Abstract]   [Full Text] [Related]  

  • 19. Appropriate use of palivizumb (Synagis).
    Graham LM; Lesnick B
    Pediatr Pulmonol Suppl; 2004; 26():156-7. PubMed ID: 15029637
    [No Abstract]   [Full Text] [Related]  

  • 20. [Prevention of respiratory syncytial virus infections with palivizumab].
    Ellingsen BB; Aase SA; Øymar K
    Tidsskr Nor Laegeforen; 2003 Apr; 123(7):941-3. PubMed ID: 12737068
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.